Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Bulimia nervosa is an eating disorder, where a person eat large amount of food in a short duration of time. Eating disorders are usually associated with mental disorders such as depression, anxiety, obsessive compulsive disorder (OCD), and others. There is no specific treatment available for the treatment of bulimia nervosa. Moreover, treatment options such as antidepressants, antipsychotics, exercises, and behavioral therapies are currently available treatment options for bulimia nervosa.

Global Bulimia Nervosa Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

COVID-19 pandemic is expected to hamper growth of the global bulimia nervosa treatment market during the forecast period. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. These challenges are hindrances for developing new treatment for bulimia nervosa.

According to National Center for Biotechnology Information, 24th August 2020, due to COVID-19 pandemic, government imposed lockdown in various parts of the world. This has led to the slowdown of all the businesses, which was the driving force for increasing unemployment among the population. Moreover, lack of social interaction have resulted in increasing cases of anxiety and depression. For instance, according to the Center for Disease Control and Prevention (CDC), 4th April 2020, the cases of depression among the U.S. population has increased by three times during the COVID-19 pandemic as compared to the year 2019, which is one of the causes of bulimia nervosa, among the population.

The global bulimia nervosa treatment is estimated to be valued at US$ 455.7 Mn in 2020, and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).

Figure 1: Global Bulimia Nervosa Treatment Market Share (%) Analysis, By Treatment Type, 2020

Bulimia Nervosa Treatment  | Coherent Market Insights

Increasing product launches for the treatment of mental illness among the population is expected to drive growth of the global bulimia nervosa treatment market over the forecast period.

Market players are indulged in product launches, which is expected to drive growth of the global bulimia nervosa treatment market over the forecast period. For instance, in 2019, Lupin Limited launched the generic version of antidepressant Fluoxetine tablets of strengths 10 mg and 20 mg in the U.S. market. Fluoxetine tablets are indicated for the treatment of bulimia nervosa, panic disorder, major depressive disorder, and others.

request-sample

Bulimia Nervosa Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 455.7 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.2% 2027 Value Projection: US$ 684.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type:
    • Drug Treatment: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Benzodiazepines, Tricyclic Antidepressants, Others.
    • Non-drug Treatment: Nutritional Therapy, Behavioral Therapy, Others.
  • By Route of Administration: Oral, Intravenous, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd

Growth Drivers:
  • Increasing number of product launches
  • Increasing approvals from regulatory authorities
  • Increasing prevalence of bulimia nervosa among the population
Restraints & Challenges:
  • Absence of proper reimbursement policies
  • Lack of awareness about the treatment options

Increasing product approvals from the regulatory authorities is expected to fuel growth of the market over the forecast period.

Market players are engaged in receiving approvals from the regulatory authorities, which is an important step for launching the product in the market. For instance, on 9th April 2020, Aurobindo Pharma received the U.S. Food and Drug Administration (U.S. FDA) approval for its generic anti-depressant Fluoxetine tablets, which will allow the manufacture and marketing of the Fluoxetine tablets of strengths 10 mg and 20 mg. The product is the generic version of Eli Lily and Company’s Prozac tablets.

Global Bulimia Nervosa Treatment Market – Restraints

Lack of proper reimbursement policies for the treatment of eating disorders is expected to restrain growth of the global bulimia nervosa treatment market over the forecast period. For instance, according to the National Eating Disorders Associations, per year, in the U.S., the total treatment cost for the eating disorders is valued at US$ 30,000 per patient. Even in the presence of insurance, the patients has to shell out more money for the treatment. Moreover, according to the same source, in the U.S., there were approximately 54,000 emergency department admissions and 23,500 in-patient hospitalizations visits due to eating disorders in the year span of 2018 – 2019, costing around US$ 29 million and US$ 209 million respectively.

Furthermore, lack of drugs specifically for the treatment of bulimia nervosa treatment and lack of awareness regarding the treatment options among the population are the factors that are expected to restrain growth of the global bulimia nervosa treatment market over the forecast period.

Global Bulimia Nervosa Treatment Market – Regional Analysis

North America is expected to hold dominant position in the global bulimia nervosa treatment market over the forecast period, owing to the increasing prevalence of the eating disorders in the region. For instance, according to the article published in the Biological Psychiatry Segment of Elsevier Journal: 2018, in the U.S., 36,309 adults suffering from eating disorders were recruited for studying the prevalence of bulimia nervosa among the population. It was estimated that, out of the total adults studied, 0.80%, 0.28%, and 0.85% of the U.S. adults were suffering from anorexia nervosa, bulimia nervosa, and binge eating disorder respectively.

Europe is also an emerging bulimia nervosa treatment market, owing to the increasing research activities for developing new treatment for the eating disorder. For instance, on 2nd March 2020, National Institute for Health Research (NIHR), in partnership with Eating Disorders Genetics Initiative (EDGI), recruited 10,000 people for studying eating disorder especially bulimia nervosa, which will help in developing novel treatment options to improve the lives of the patients suffering from eating disorder.

Figure 2: Global Bulimia Nervosa Treatment Market Share (US$ Mn), by Region, 2020

Bulimia Nervosa Treatment  | Coherent Market Insights

Global Bulimia Nervosa Treatment Market – Competitive Landscape

Some of the key players operating in the global bulimia nervosa treatment market include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.

Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.

Market Dynamics

Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.

Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.

Key features of the study:

  • This report provides an in-depth analysis of global bulimia nervosa treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global bulimia nervosa treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market

Detailed Segmentation:

  • Global Bulimia Nervosa Treatment Market, By Treatment Type:
    • Drug Treatment
    • Selective Serotonin Reuptake Inhibitor (SSRI)
    • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
    • Benzodiazepines
    • Tricyclic Antidepressants
    • Others
    • Non-drug Treatment
    • Nutritional Therapy
    • Behavioral Therapy
    • Others
  • Global Bulimia Nervosa Treatment Market, By Route of Administration:
    • Oral
    • Intravenous
    • Others
  • Global Bulimia Nervosa Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bulimia Nervosa Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
      • By Treatment Type:
        • Drug Treatment
          • Selective Serotonin Reuptake Inhibitor (SSRI)
          • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
          • Benzodiazepines
          • Tricyclic Antidepressants
          • Others
        • Non-Drug Treatment
          • Nutritional Therapy
          • Behavioral Therapy
          • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Treatment Type:
        • Drug Treatment
          • Selective Serotonin Reuptake Inhibitor (SSRI)
          • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
          • Benzodiazepines
          • Tricyclic Antidepressants
          • Others
        • Non-Drug Treatment
          • Nutritional Therapy
          • Behavioral Therapy
          • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Treatment Type:
        • Drug Treatment
          • Selective Serotonin Reuptake Inhibitor (SSRI)
          • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
          • Benzodiazepines
          • Tricyclic Antidepressants
          • Others
        • Non-Drug Treatment
          • Nutritional Therapy
          • Behavioral Therapy
          • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Treatment Type:
        • Drug Treatment
          • Selective Serotonin Reuptake Inhibitor (SSRI)
          • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
          • Benzodiazepines
          • Tricyclic Antidepressants
          • Others
        • Non-Drug Treatment
          • Nutritional Therapy
          • Behavioral Therapy
          • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Treatment Type:
        • Drug Treatment
          • Selective Serotonin Reuptake Inhibitor (SSRI)
          • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
          • Benzodiazepines
          • Tricyclic Antidepressants
          • Others
        • Non-Drug Treatment
          • Nutritional Therapy
          • Behavioral Therapy
          • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Treatment Type:
        • Drug Treatment
          • Selective Serotonin Reuptake Inhibitor (SSRI)
          • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
          • Benzodiazepines
          • Tricyclic Antidepressants
          • Others
        • Non-Drug Treatment
          • Nutritional Therapy
          • Behavioral Therapy
          • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Allergan, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Eli Lilly and Company
    • AstraZeneca plc
    • Alembic Pharmaceuticals Ltd
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Reddy’s Laboratories Limited
    • Lupin Pharmaceuticals, Inc.
    • Aurobindo Pharma
    • Zydus Cadila
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Product launches
    • Acquisition and Merger Scenario
  4. Bulimia Nervosa Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
    • During COVID-19 Market Situation
    • Supply Side and Demand Side Analysis
    • Impact of COVID-19 on Depression and Eating Disorders
    • Government Initiatives to Combat COVID-19
  5. Global Bulimia Nervosa Treatment Market, By Treatment Type , 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Drug Treatment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-drug Treatment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  6. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  8. Global Bulimia Nervosa Treatment Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Allergan, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Alembic Pharmaceuticals Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Johnson & Johnson Services, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Reddy’s Laboratories Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Lupin Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Aurobindo Pharma
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Zydus Cadila
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Apotex Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sun Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 28 figures on "Global Bulimia Nervosa Treatment Market” - Global Forecast to 2027”.

FAQgrowicon

Frequently Asked Questions

The global bulimia nervosa treatment market is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).
The global bulimia nervosa treatment market is estimated to be valued at US$ 455.7 million in 2020.
Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd are some of the prominent players operating in the global bulimia nervosa treatment market.
The global bulimia nervosa treatment market is expected to be valued at US$ 684.0 million in 2027.
Drug treatment is the most common treatment prescribed for the treatment of bulimia nervosa.
North America is the prominent region in the global bulimia nervosa treatment market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner